Imatinib in combination with CD19-CAR T cells was highly active in the killing of RUNX1 mutant CML BC cells and the latter was able to successfully kill imatinib-resistant clones. Here, CD19 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.